Ascendis Pharma A (ASND) Gross Margin (2021 - 2026)
Ascendis Pharma A (ASND) posted Gross Margin of 92.9% for Q1 2026, up 72.79% sequentially from 53.76% in Q4 2025, and up 1025.0% YoY from 8.26% in Q1 2025.
Ascendis Pharma A (ASND) Gross Margin (2021 - 2026) Analysis & Trends
Ascendis Pharma A has reported Gross Margin for 6 years, with the latest figure at 92.9% in Q1 2026.
- Quarterly Gross Margin rose 1025.0% year-over-year to 92.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74.51% (up 1221.0% YoY) and the FY2025 annual result came in at 86.82%, down 190.0% from the prior year.
- Gross Margin advanced to 92.9% in Q1 2026 per ASND's latest filing, from 53.76% in the prior quarter.
- Over five years, Gross Margin peaked at 92.9% in Q1 2026 and troughed at 37.81% in Q1 2022.
- A 5-year average of 74.17% and a median of 80.63% in 2024 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 7608 bps in 2022, down 6219 bps in 2022.
- Over 5 years, Gross Margin stood at 77.68% in 2022, then slumped by 50 bps to 39.06% in 2023, then jumped by 32 bps to 51.58% in 2024, then climbed by 4 bps to 53.76% in 2025, then jumped by 73 bps to 92.9% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 92.9%, 53.76%, and 89.54% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 92.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.90% |
| Dec 31, 2025 | 53.76% |
| Sep 30, 2025 | 89.54% |
| Jun 30, 2025 | 80.10% |
| Mar 31, 2025 | 82.65% |
| Dec 31, 2024 | 51.58% |
| Sep 30, 2024 | 80.63% |
| Jun 30, 2024 | 68.15% |
| Mar 31, 2024 | 92.11% |
| Dec 31, 2023 | 39.06% |
| Sep 30, 2023 | 84.62% |
| Jun 30, 2023 | 72.72% |
| Mar 31, 2023 | 86.24% |
| Dec 31, 2022 | 77.68% |
| Sep 30, 2022 | 88.93% |
| Jun 30, 2022 | 82.37% |
| Mar 31, 2022 | 37.81% |
| Dec 31, 2021 | 1.60% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |